Brief: Calliditas Q1 Operating Loss At SEK 208.4 Million
18/05/2022 06:02
May 18 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* INTERIM REPORT Q1, 2022
* Q1 NET SALES AMOUNTED TO SEK 49.7 MILLION, WHEREOF TARPEYO
NET
SALES AMOUNTED TO SEK 18.0 MILLIO
* Q1 OPERATING LOSS AMOUNTED TO SEK 208.4 MILLION AND SEK
150.8
MILLION FOR THREE MONTHS ENDED MARCH 31, 2022 AND 2021,
RESPECTIVELY
Source text for Eikon: ID:nWkr553ZHR
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations